Abstract:We revisited the "Xiao Chaihu Decoction event (XCHDE)" occurred in late 1980s in Japan and the Bupleuri Radix related adverse drug reaction (ADR) reports in China After careful review, comparison, analysis and evaluation, we think the interstitial pneumonitis, drug induced Liver injury (DILI) and other severe adverse drug envents (ADEs) including death happened in Japan is probably results from multiple factors, including combinatory use of XCHDE with interferon, Kampo usage under modern medicine theory guidance, and use of XCHD on the basis of disease diagnosis instead of traditional Chinese syndrome complex differentiation. There are less ADE case reports related to XCHD preparation in China compared to Japan, mostly manifest with hypersensitivity responses of skin and perfuse perspiration. The symptoms of Radix Bupleuri injection related ADEs mainly manifest hypersensitivity-like response, 2 cases of intravenous infusion instead of intramuscular injection developed hypokalemia and renal failure. One case died from severe hypersensitivity shock. In Chinese literatures, there is no report of the interstitial pneumonitis and DILI associated with XCHDG in Japan. So far, there is no voluntary monitoring data and large sample clinical research data available. The author elaborated the classification of "reevaluation" and clarified "re-evaluation upon events" included the reaction to the suspected safety and efficacy events. Based on the current status of the clinical research on the Radix Bupleuri preparations, the author points out that post-marketing "re-evaluation upon suspected event" is not only a necessity of continuous evaluation of the safety, efficacy of drugs, it is also a necessity for providing objective clinical research data to share with the international and domestic drug administrations in the risk-benefit evaluation. It is also the unavoidable pathway to culture and push the excellent species and famous brands of TCM to the international market, in that it enhances the pharmaceutical manufactures the ability to control enterprise risk and eliminate the negative impact on traditional Chinese medicine. With the widely used and ADR report concentrated Radix Bupleuri injection as an example, the author provide a new approach to post-marketing clinical research.

The Discussion on strategy improving the safety in human bioequivalence study

The Discussion on Several Key Questions in Human Bioequivalence Study of Oral Preparation of Terazosin Hydrochloride

Opinions and suggestions of bioequivalent studies on modified new drugs

Discussions on the standardized safety evaluation of new drugs in phase I clinical trials

The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities

Implementation of Quality by Design in the Program of Safety Re-evaluation of TCM Injections

A Systematic Review and Qualitative Analysis or the Definition and Scope of Drug Safety in China

An Adaptive Three‐Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re‐Estimation and Optimized Allocation Ratio

Discussion on the problems and strategies in bioequivalence tests of drug preparations

Considerations on the repeated bioequivalence studies in control of the type I error

Analysis on Concept of Drug Safety According to the Result of Qualitative Interview

Comparison between two different bioequivalence designs with within-subject variation around 30％

Sample size determination and post hoc statistical power in bioequivalence studies

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

Analysis and discussion on the subject complaint in clinical drug trials

'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors

Questions in the Bioequivalence Tests of the Preparations Containing Metformin Hydrochloride

Improving the management level of clinical trial based on the establishment of drug clinical trial center pharmacy

["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations]

[Safety Assessment in Radomized Controlled Clinical Trials].

CHINA STATUS III: A One Year Registry Study Performed in China Using a Valsartan/amlodipine Single-Pill Combination-Based Long-Term Blood Pressure Management in Hypertension Patients: Results of the Interim Analysis at 6 Months